Your browser doesn't support javascript.
loading
Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial.
Shenoy, Manjunath M; De, Abhishek; Shah, Bela; Das, Anupam; Saraswat, Abir; Lahiri, Koushik; Yadav, Sheetal; Sarda, Aarti; Chakraborty, Disha; J, Dharmender; Kamat, Shruti; Doshi, Yashika; Gonsalves, Nelry; Choudhary, Ankita; Dhoot, Dhiraj; Mahadkar, Namrata; Bhushan, Sumit; Gadkari, Rujuta; Barkate, Hanmant.
Afiliación
  • Shenoy MM; Department of Dermatology, Omega Hospital, Mangalore, Karnataka, India.
  • De A; Department of Dermatology, Wizderm Specialty Skin and Hair Clinic, Kolkata, West Bengal, India.
  • Shah B; Department of Dermatology, BJ Medical College and Civil Hospital, Ahmedabad, Gujarat, India.
  • Das A; Department of Dermatology, Iris Multispecialty Hospital, Kolkata, West Bengal, India.
  • Saraswat A; Department of Dermatology, Indushree Skin Clinic, Lucknow, Uttar Pradesh, India.
  • Lahiri K; Department of Dermatology, Wizderm Specialty Skin and Hair Clinic, Kolkata, West Bengal, India.
  • Yadav S; Department of Dermatology, ABVIMS and Dr. RML Hospital, New Delhi, India.
  • Sarda A; Department of Dermatology, Wizderm Specialty Skin and Hair Clinic, Kolkata, West Bengal, India.
  • Chakraborty D; Department of Dermatology, Calcutta National Medical College, Kolkata, West Bengal, India.
  • J D; Department of Dermatology, Wizderm Specialty Skin and Hair Clinic, Kolkata, West Bengal, India.
  • Kamat S; Department of Dermatology, Wizderm Specialty Skin and Hair Clinic, Kolkata, West Bengal, India.
  • Doshi Y; Department of Dermatology, Wizderm Specialty Skin and Hair Clinic, Kolkata, West Bengal, India.
  • Gonsalves N; Department of Dermatology, Wizderm Specialty Skin and Hair Clinic, Kolkata, West Bengal, India.
  • Choudhary A; Department of Dermatology, Wizderm Specialty Skin and Hair Clinic, Kolkata, West Bengal, India.
  • Dhoot D; Department of Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, India.
  • Mahadkar N; Department of Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, India.
  • Bhushan S; Department of Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, India.
  • Gadkari R; Department of Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, India.
  • Barkate H; Department of Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, India.
Drug Des Devel Ther ; 17: 2899-2908, 2023.
Article en En | MEDLINE | ID: mdl-37766823
ABSTRACT

Introduction:

Itraconazole follows non-linear pharmacokinetics and hence is recommended once daily, but in real-world practice, is commonly prescribed as twice daily. Hence, this study aimed to evaluate the efficacy and safety of super-bioavailable-itraconazole-130 mg (SB-130) and conventional-itraconazole-200 mg (CITZ-200) once daily compared with conventional-itraconazole-100 mg (CITZ-100) twice daily in glabrous tinea.

Methods:

A total of 261 eligible patients were enrolled in this prospective, randomized, clinical study from December-2021 to August-2022 at seven centers in India. Efficacy and safety assessments were done at week-3 and 6, with follow-up at week-10 for relapse. The primary objective was to assess the proportion of patients who achieved complete cure at week-6 following treatment in all itraconazole groups. The secondary outcomes were safety and clinical and mycological cure rates.

Results:

Of 261 patients, 240 were included in the analysis. At week-6, 140 patients were completely cured; thus, overall cure rate was 58.33%. Fifty-five patients (69%) in SB-130 while 47/77 (61%) and 38/83 (46%) patients were completely cured in CITZ-200 and CITZ-100 groups respectively (p<0.05; SB-130 CITZ-100, p=0.32; SB-130 CITZ-200, p=0.058; CITZ-200 CITZ-100). There was no statistical difference in the mycological cure rate and area clearance rate between any of the groups (p=0.14); however, a statistically significant difference was noted for OD dosing over BD dosing in achieving clinical cure rates (p<0.05). A total of 13/140 patients (9%) relapsed following complete cure, with no statistically significant difference between any of the groups (p=0.50). All treatments were safe and well-tolerated, with no discontinuation.

Conclusion:

In this clinical study, moderate efficacy with all doses of ITZ was reported but was better with OD dosing. Although there was no statistical difference between SB-130 and CITZ-200, SB-130 may be preferred over CITZ-200 owing to the advantage of SB over the conventional ITZ.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tiña / Itraconazol Tipo de estudio: Clinical_trials / Observational_studies Límite: Humans Idioma: En Revista: Drug Des Devel Ther Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: India

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tiña / Itraconazol Tipo de estudio: Clinical_trials / Observational_studies Límite: Humans Idioma: En Revista: Drug Des Devel Ther Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: India